Luye Pharma Group Ltd (2186)

Hong Kong

Currency in HKD

2186 Pro Research

2.05

-0.07(-3.31%)

Closed·14/08

Fair Value

Unlock Value

Day's Range

2.03

2.12

52 wk Range

1.73

4.05

2186 Income Statement

Assess the Luye Pharma Group income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the 2186 net worth.

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

5,200.23

5,981.66

6,143.08

6,061.44

6,308.37

Total Revenues Growth

aa.aa

-6.13%

+15.03%

+2.7%

-1.33%

+4.07%

Cost Of Revenues

aa.aa

1,803.49

1,841.14

1,938.9

2,017.21

2,145.79

Gross Profit

aa.aa

3,396.74

4,140.52

4,204.18

4,044.23

4,162.58

Gross Profit Growth

aa.aa

-14.88%

+21.9%

+1.54%

-3.8%

+2.93%

Gross Profit Margin %

aa.aa

65.32%

69.22%

68.44%

66.72%

65.99%

Other Operating Expenses, Total

aa.aa

3,033.34

3,351.38

3,316.74

2,907.65

2,944.94

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+1.04%	+10.48%	-1.03%	-12.33%	+1.28%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2,275.62	2,402.56	2,700.13	2,398.39	2,505.79
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	757.72	948.82	616.6	509.26	439.15

Operating Income

aa.aa

363.4

789.14

887.44

1,136.58

1,217.64

Operating Income Growth

aa.aa

-63.23%

+117.16%

+12.46%

+28.07%

+7.13%

EBIT Margin %

aa.aa

6.99%

13.19%

14.45%

18.75%

19.3%

Net Interest Expenses

aa.aa

-209.77

-295.65

-465.49

-404.59

-533.8

Net Interest Expenses Growth

aa.aa

+23.15%

-40.94%

-57.44%

+13.08%

-31.93%

Interest Expense, Total

aa.aa

-399.46

-471.76

-675.45

-561.79

-686.6

Interest And Investment Income

aa.aa

189.69

176.1

209.97

157.19

152.8

Other Non Operating Expenses, Total

aa.aa

106.26

216.11

288.6

110

130.12

EBT, Excl. Unusual Items

aa.aa

259.88

709.59

710.54

841.98

813.97

Gain (Loss) On Sale Of Assets

aa.aa

11.36

-0.21

1.5

18.49

-4.96

Other Unusual Items, Total

aa.aa

-330.99

-41.17

-13.88

-23.04

-13.41

EBT, Incl. Unusual Items

aa.aa

-74.56

669.76

700.1

839.22

944.64

EBT, Incl. Unusual Items Growth

aa.aa

-107.91%

+998.32%

+4.53%

+19.87%

+12.56%

EBT, Incl. Unusual Items Margin

aa.aa

-1.43%

11.2%

11.4%

13.85%

14.97%

Income Tax Expense

aa.aa

70.23

86.47

161.02

194.21

238.98

Net Income to Company

aa.aa

-144.78

583.3

539.08

645.01

705.66

Minority Interest

aa.aa

10.39

21.51

-6.47

-173.12

-86.91

Net Income

aa.aa

-134.39

604.81

532.61

471.89

618.75

Net Income Growth

aa.aa

-119.02%

+550.03%

-11.94%

-11.4%

+31.12%

Net Income Margin %

aa.aa

-2.58%

10.11%

8.67%

7.79%

9.81%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-134.39

604.81

532.61

471.89

618.75

Basic EPS - Continuing Operations

aa.aa

-0.04

0.17

0.14

0.13

0.16

Basic EPS - Continuing Operations Growth

aa.aa

-117.59%

+545.46%

-17.78%

-12.19%

+26.61%

Diluted EPS - Continuing Operations

aa.aa

-0.04

0.17

0.14

0.13

0.16

Diluted EPS - Continuing Operations Growth

aa.aa

-117.63%

+545.46%

-17.78%

-12.22%

+26.65%

Basic Weighted Average Shares Outstanding

aa.aa

3,445.43

3,480.85

3,728.36

3,761.67

3,895.81

Diluted Weighted Average Shares Outstanding

aa.aa

3,445.43

3,480.85

3,728.36

3,761.67

3,895.81

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

906.88

1,425.61

1,552.91

1,891.57

2,014.38

EBITDA Growth

aa.aa

-38.19%

+57.2%

+8.93%

+21.81%

+6.49%

EBITDA Margin %

aa.aa

17.44%

23.83%

25.28%

31.21%

31.93%

EBIT

aa.aa

363.4

789.14

887.44

1,136.58

1,217.64

* In Millions of CNY (except for per share items)

FAQ

What was Luye Pharma Group’s revenue at year end?

At the end of the last reported fiscal year, Luye Pharma Group (2186) recorded total revenue of 6,308.37 million CNY.

How much revenue did Luye Pharma Group report in the most recent quarter?

In its most recent quarterly earnings report, Luye Pharma Group posted revenue of 3,127.26 million CNY.

What was Luye Pharma Group’s net income for the year?

For the full year, Luye Pharma Group reported net income of 618.75 million CNY.

How much net income did Luye Pharma Group post in the last quarter?

In the most recent quarter, Luye Pharma Group (2186) posted net income of 305.86 million CNY.

What was Luye Pharma Group’s gross profit for the year?

Gross profit for the year was reported at 4,162.58 million CNY.

How much gross profit did Luye Pharma Group generate last quarter?

Luye Pharma Group recorded gross profit of 2,004.97 million CNY in its latest quarterly report.

What was Luye Pharma Group’s annual operating income?

For the full year, Luye Pharma Group (2186) reported operating income of 1,217.64 million CNY.

What was Luye Pharma Group’s operating income last quarter?

Quarterly operating income was 607.32 million CNY.

What was Luye Pharma Group’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at 1,010.81 million CNY.

What was the quarter-over-quarter change in EBITDA for Luye Pharma Group?

EBITDA changed by 0.72% million CNY compared to the last quarter.

How did Luye Pharma Group’s revenue change compared to the previous quarter?

Revenue changed by -1.69% million CNY compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Luye Pharma Group?

In the latest quarter, gross profit changed by -7.07% million CNY from the previous quarter.

S&P/TSX

36,730.27

-29.02

-0.08%

S&P/TSX 60

2,164.23

-4.11

-0.19%

US 30

53,704.20

-135.9

-0.25%

US 500

7,781.40

-17.8

-0.23%

S&P 500 VIX

14.25

-0.38

-2.60%

DAX

26,440.31

+140.57

+0.53%

Dollar Index

99.54

-0.320

-0.32%

Market Movers

Name	Last	Chg. %	Vol.
Enbridge	70.61	-1.20%	12.94M
Canadian Natural	66.41	+0.09%	9.20M
RBC	300.70	+0.42%	1.78M
Toronto Dominion Bank	172.61	+0.60%	2.58M
Shopify Inc	214.35	-3.00%	1.45M
Manulife Financial	61.73	+0.82%	4.15M
Suncor Energy	91.44	+0.23%	2.56M

Name	Last	Chg. %	Vol.
Prospectiva	0.90	+408.68%	18.00K
Metaguestai	0.03	+200.00%	93.75K
Metaguestai	0.03	+200.00%	93.75K
Lithos Energy	0.150	+200.00%	37.00K
DGTL	0.0250	+150.00%	10.00K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
Canadian Chrome	0.010	+100.00%	1.06M

Name	Last	Chg. %	Vol.
Lanebury Growth Capital	0.05	-68.75%	18.17K
Asep Medical Holdings	0.06	-60.71%	2.95K
Lithos Energy	0.10	-60.00%	8.00K
Carson River Ventures	0.04	-50.00%	1.25K
James Bay Resources Ltd	0.010	-50.00%	1.00K
Albert Labs International	0.005	-50.00%	1.00K
Molecule Holdings	0.005	-50.00%	20.11K

Trending Stocks

Name	Last	Chg. %	Vol.
Air Canada	29.64	-2.53%	2.82M
TELUS	13.54	+0.59%	6.62M
Celestica Inc.	465.23	-4.02%	329.60K
Keel Infra	4.87	+4.96%	4.50M
HIVE Digital Tech	3.7200	+3.05%	2.34M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaa	131.33	+52.90%	200.80
Aaa Aaaa Aaaa Aaaaa	101.88	+45.96%	148.70
Aa Aaa A	9.02	+45.24%	13.10
A Aaaaaaaa	16.94	+44.81%	24.53
Aaa Aaaaaaaaa	30.56	+43.89%	43.97
Aaaaaaaa Aaa	5.40	+43.06%	7.73
Aaaaaaaaaaaaaaaaaa A	34.06	+40.38%	47.81

Name	Last	Upside	Fair Value
Aaaaaaa	131.33	+52.90%	200.80
Aaa Aaaa Aaaa Aaaaa	101.88	+45.96%	148.70
Aa Aaa A	9.02	+45.24%	13.10
A Aaaaaaaa	16.94	+44.81%	24.53
Aaa Aaaaaaaaa	30.56	+43.89%	43.97
Aaaaaaaa Aaa	5.40	+43.06%	7.73
Aaaaaaaaaaaaaaaaaa A	34.06	+40.38%	47.81

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Luye Pharma Group Ltd (2186)

2186 Income Statement

FAQ

What was Luye Pharma Group’s revenue at year end?

How much revenue did Luye Pharma Group report in the most recent quarter?

What was Luye Pharma Group’s net income for the year?

How much net income did Luye Pharma Group post in the last quarter?

What was Luye Pharma Group’s gross profit for the year?

How much gross profit did Luye Pharma Group generate last quarter?

What was Luye Pharma Group’s annual operating income?

What was Luye Pharma Group’s operating income last quarter?

What was Luye Pharma Group’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Luye Pharma Group?

How did Luye Pharma Group’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Luye Pharma Group?

Trending Stocks